Zhengbo Song1, Xinmin Yu, Chunxiao He, Beibei Zhang, Yiping Zhang. 1. Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China; ; Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou 310022, China.
Abstract
OBJECTIVE: Few treatment options are available for advanced non-small cell lung cancer (NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. The aim of this study was to investigate the efficacy of re-administration of the same TKI after failure of gefitinib or erlotinib. PATIENTS AND METHODS: The clinical data of 33 patients with advanced NSCLC were retrospectively analyzed. All of the patients were given the same TKI treatment after the failure of gefitinib or erlotinib. Survival analysis was evaluated by Kaplan-Meier method. RESULTS: Twenty patients (60.6%) were re-administration with gefitinib as the 2(nd) EGFR-TKI, and thirteen patients (39.4%) received erlotinib. One patient (3.0%) showed partial response (PR), 14 (42.4%) achieved stable disease (SD), and 18 (54.5%) had progressive disease (PD). The disease control rate was 45.5% and the median progression-free survival was 1.5 months (95% CI: 0.6-2.3 months). The PFS in patients who got disease control in the prior TKI was 2.2 and 1.2 months in the progression disease cases (P=0.29), the DCR was 54.5% and 27.3% in two group, respectively (P=0.26). CONCLUSIONS: Re-administration of TKI seems to be a potential therapeutic option for treatment of selected advanced NSCLC patients after failure of gefitinib or erlotinib, especially for the patients with NSCLC who once responded from the prior TKI treatment.
OBJECTIVE: Few treatment options are available for advanced non-small cell lung cancer (NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. The aim of this study was to investigate the efficacy of re-administration of the same TKI after failure of gefitinib or erlotinib. PATIENTS AND METHODS: The clinical data of 33 patients with advanced NSCLC were retrospectively analyzed. All of the patients were given the same TKI treatment after the failure of gefitinib or erlotinib. Survival analysis was evaluated by Kaplan-Meier method. RESULTS: Twenty patients (60.6%) were re-administration with gefitinib as the 2(nd) EGFR-TKI, and thirteen patients (39.4%) received erlotinib. One patient (3.0%) showed partial response (PR), 14 (42.4%) achieved stable disease (SD), and 18 (54.5%) had progressive disease (PD). The disease control rate was 45.5% and the median progression-free survival was 1.5 months (95% CI: 0.6-2.3 months). The PFS in patients who got disease control in the prior TKI was 2.2 and 1.2 months in the progression disease cases (P=0.29), the DCR was 54.5% and 27.3% in two group, respectively (P=0.26). CONCLUSIONS: Re-administration of TKI seems to be a potential therapeutic option for treatment of selected advanced NSCLCpatients after failure of gefitinib or erlotinib, especially for the patients with NSCLC who once responded from the prior TKI treatment.
Entities:
Keywords:
Non-small cell lung cancer (NSCLC); efficacy; erlotinib; gefitinib; retreatment
Authors: Sandra Van Schaeybroeck; Anthi Karaiskou-McCaul; Donal Kelly; Daniel Longley; Leeona Galligan; Eric Van Cutsem; Patrick Johnston Journal: Clin Cancer Res Date: 2005-10-15 Impact factor: 12.531
Authors: A Becker; L Crombag; D A M Heideman; F B Thunnissen; A W van Wijk; P E Postmus; E F Smit Journal: Eur J Cancer Date: 2011-07-23 Impact factor: 9.162
Authors: Gregory J Riely; Mark G Kris; Binsheng Zhao; Tim Akhurst; Daniel T Milton; Erin Moore; Leslie Tyson; William Pao; Naiyer A Rizvi; Lawrence H Schwartz; Vincent A Miller Journal: Clin Cancer Res Date: 2007-09-01 Impact factor: 12.531